University of Science, Technique and Technology of Bamako (Usttb)
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sagara, Issaka
CALINA, NCT04300309: Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria

Terminated
2/3
28
RoW
artemether:lumefantrine (2.5 mg:30 mg)
Novartis Pharmaceuticals, European and Developing Countries Clinical Trials Partnership (EDCTP), Medicines for Malaria Venture (MMV), Switzerland, Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso, Institut de Recherche en sciences de la Santé - Unité de Recherche Clinique de Nanoro (IRSS-URCN), Burkina Faso
Plasmodium Falciparum Malaria
07/23
05/24
NCT04940130: PfSPZ Vaccine Trial in Malian Children

Completed
2
290
RoW
Sanaria® PfSPZ Vaccine, Normal Saline
Sanaria Inc., Malaria Research and Training Center, Bamako, Mali, University of the Sciences, Techniques and Technologies of Bamako, National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Malaria,Falciparum
12/22
12/22
NCT05135273: Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali

Completed
1
80
RoW
Pfs230D1-EPA/Matrix-M Vaccine, Verorab Rabies Vaccine
National Institute of Allergy and Infectious Diseases (NIAID), Novavax, Malaria Research and Training Center, Bamako, Mali
Malaria,Falciparum
02/23
06/23
NCT06507605: Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults

Not yet recruiting
1
240
RoW
R21, Pfs230D1-CRM197, Pfs230D1-EPA, Matrix-M
Serum Institute of India Pvt. Ltd., National Institute of Allergy and Infectious Diseases (NIAID)
Prevention of Malaria Transmission and Clinical Malaria
04/25
10/25

Download Options